INTRAROSA

Peak

prasterone

NDAVAGINALINSERT
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

12.1 Mechanism of Action Prasterone is an inactive endogenous steroid and is converted into active androgens and/or estrogens. The mechanism of action of INTRAROSA in postmenopausal women with vulvar and vaginal atrophy is not fully established. 12.3 Pharmacokinetics In a study conducted in…

Clinical Trials (2)

NCT04982692Phase 3Completed

A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy

Started Sep 2021
417 enrolled
Postmenopausal Vulvovaginal Atrophy
NCT01376349Phase 3Completed

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Started Jul 2011
464 enrolled
Breast CancerGynecologic Cancer

Loss of Exclusivity

LOE Date
Mar 19, 2031
61 months away
Patent Expiry
Mar 19, 2031

Patent Records (3)

Patent #ExpiryTypeUse Code
8629129
Aug 7, 2028
Product
8957054
Jan 8, 2030
U-1922
8268806
Mar 19, 2031
Product